SRNE, US83587F2020

Sorrento Therapeutics stock heads toward its November 6 report at USD 0.0008

Published on 10/07/2026 at 05:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sorrento Therapeutics stock was last at USD 0.0008 on October 6, 2026, against a 52-week range of USD 0.0001 to USD 0.0502. Its next report is set for November 6, 2026.

SRNE, US83587F2020, Illustration mit AI erstellt.

Sorrento Therapeutics (ISIN US83587F2020) was last at USD 0.0008 on OTC Markets on October 6, 2026, with a market capitalization of USD 0.4 million. The next scheduled reporting date is November 6, 2026, according to Investing.com.

Price stays near yearly low

The USD 0.0008 quote sits within a 52-week range of USD 0.0001 to USD 0.0502, leaving the stock 98.4 percent below the upper boundary. The same October 6 data show an intraday range of USD 0.0005 to USD 0.0008, placing the last quote at the session high.

The market value gives the price context: USD 0.4 million is a fraction of the company's former public-market scale, while the share price remains eight times the 52-week low. Trade Ideas also reports a USD 0.0008 closing level on October 5, 2026, and a year-to-date decline of 69.23 percent.

Biotech assets meet liquidation history

Sorrento operates in biotechnology, with programs covering cancer, pain and infectious diseases. Its portfolio has included antibody and cellular immunotherapies, the Sofusa drug-delivery platform and the RTX pain candidate, according to Investing.com.

The company's legal and operating backdrop remains central to the stock's valuation. Sorrento filed for Chapter 11 protection on February 13, 2023, and its plan was approved as a Chapter 11 liquidation on November 30, 2023, according to Investing.com.

Bankruptcy litigation remains a factor

Legal proceedings continue to shape the company's public record. Law360 reported on June 29, 2026, that a Texas bankruptcy judge blocked racketeering claims involving Sorrento, while a California federal judge had paused related shareholder litigation on June 26, 2026.

For the November 6 checkpoint, the key figures are the USD 0.0008 quote, the USD 0.4 million market capitalization and the 98.4 percent gap to the 52-week high. The scheduled date gives investors a concrete point for assessing whether the company can provide fresh operating information.